ResMed (ASX:RMD, NYSE:RMD) is not being punished for a weak quarter.
That is what makes the recent share price pressure more interesting. The sleep apnea device giant delivered higher revenue, wider margins and strong cash generation in its third-quarter FY2026 result. Yet investors have continued to mark the stock down, with the US-listed shares recently sitting more than 30% below their 52-week high.
The market is not arguing with the latest numbers. It is arguing with the long-term story.
The Quarter Was Stronger Than the Share Price Suggests
ResMed’s Q3 FY2026 update was solid on the surface and cleaner underneath.
Revenue rose 11% to US$1.4 billion, or 8% on a constant currency basis. Non-GAAP gross margin expanded 290 basis points to 62.8%, while non-GAAP diluted earnings per share rose to US$2.86. Operating cash flow reached US$554 million for the quarter.
Those numbers matter because they show the business is still scaling. Supply chain pressure has eased, pricing and product mix appear supportive, and the company is still turning revenue growth into earnings and cash flow.
The market’s problem is not the quarter. It is the question sitting beyond it.
GLP-1 Fears Are Still Setting the Mood
The main concern remains GLP-1 weight-loss drugs.
Obesity is a major risk factor for obstructive sleep apnea, which is ResMed’s core treatment market. That creates an obvious investor fear: if drugs such as Ozempic, Wegovy and Mounjaro help more patients lose weight, the long-term pool of patients needing CPAP therapy may shrink.
ResMed has pushed back against that reading. Management has previously pointed to patient data suggesting GLP-1 users are more likely to start CPAP therapy and may remain engaged with treatment for longer.
That is the bull case in plain English: GLP-1 drugs may bring more patients into the healthcare system, increasing diagnosis and treatment rather than reducing it.
The bear case is simpler. Even if ResMed is right today, investors may still apply a lower multiple until they have several more years of evidence. In markets, uncertainty does not need to be fatal to be expensive.
Noctrix Adds Growth, But Also Execution Risk
ResMed’s acquisition of Noctrix Health adds another layer to the debate.
The company completed the US$340 million deal in June 2026, adding Noctrix’s Nidra therapy for moderate-to-severe restless legs syndrome to its sleep health portfolio.
Strategically, the fit is clear. ResMed already sells into sleep and respiratory care. Noctrix gives it exposure to an adjacent sleep disorder, with a device-based therapy that may sit naturally beside its existing clinical network.
Still, acquisitions create new questions. Investors will want to know how quickly Noctrix can scale, what margins look like, and whether ResMed can integrate the business without pulling focus from its core sleep apnea franchise.
A good deal can extend a growth runway. A new deal can also make a nervous market ask for more proof.
The CFO Change Lands at a Sensitive Time
ResMed also announced a finance leadership change alongside its Q3 update. Brett Sandercock retired as Chief Financial Officer effective 4 May 2026, after 27 years with the company, including 20 years as CFO. Aaron Bloomer was appointed as his successor.
On its own, a planned CFO transition is not a problem. Large companies manage succession regularly. The timing is what gives it more weight.
ResMed is dealing with a valuation reset, GLP-1 scepticism and a fresh acquisition. A new CFO now has to help explain the next phase of the story while investors are already looking closely at margins, cash flow and capital allocation.
The Next Test Is Evidence, Not Another Promise
The bull case is that ResMed keeps proving demand for CPAP therapy remains durable, while expanding its sleep health platform and maintaining strong margins.
The bear case is that GLP-1 uncertainty keeps weighing on the multiple, even if the company keeps producing respectable results. Noctrix adds another test, because the market will want evidence that the deal can become more than a bolt-on headline.
For now, ResMed’s story is not broken. It is being questioned. The next few quarters will show whether strong operating numbers are enough to calm a market that is still worried about what sleep medicine looks like five years from now.
